Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups Meeting Abstract
| Authors: | Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M. S.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S.; Chen, C.; Raje, N.; Scheid, C.; Delforge, M.; Larsen, J.; Pabst, T.; Suzuki, K.; Truppel-Hartmann, A.; Yang, Z.; Piasecki, J.; Felten, J.; Caia, A.; Cook, M.; Giralt, S.; Mateos, M. V. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | high-risk; progression-free survival; mm; car t; triple-class-exposed |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S497 |
| End Page: | S498 |
| Language: | English |
| ACCESSION: | WOS:001062479600580 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01449-0 |
| Notes: | Meeting Abstract: MM-388 -- Source: Wos |
